Mon Dec 16 22:30:15 UTC 2024: **Hamps Bio IPO Oversubscribed on Day 1**

**MUMBAI, December 13, 2024** – The initial public offering (IPO) of Hamps Bio Ltd., a small and medium enterprise (SME), was fully subscribed within two hours of its launch on Friday. The ₹6.22 crore IPO, offered at a fixed price of ₹51 per share, saw 3.4 times oversubscription by midday, driven primarily by strong retail investor demand.

Retail investors alone oversubscribed their allotted portion by 6.27 times, while the Non-Institutional Investors (NII) segment saw only 53% subscription. The IPO, consisting of a fresh issue of 12.2 lakh shares, is open for subscription until December 17th. The allotment is expected on December 18th, with shares credited to successful bidders’ Demat accounts by December 19th. Listing on the BSE SME platform is scheduled for December 20th.

Hamps Bio, established in 2007, operates in pharmaceutical formulations and freeze-dried ingredient manufacturing and distribution, marketing products under the “Hamps” and “FzyEzy” brands. The company plans to utilize IPO proceeds for purchasing plant and machinery for its FMCG division, brand promotion, and general corporate purposes. In FY24, Hamps Bio reported a 16.4% revenue increase to ₹6.5 crore and a 39.5% surge in net profit to ₹50.07 lakh. Marwadi Chandarana Intermediaries Brokers Pvt. Ltd. is the book-running lead manager.

Read More